SWOG clinical trial number
SWOG-9445
Prognostic Factor Panel to Predict Preferred Therapy for Node Positive Postmenopausal Breast Cancer Patients (CAF vs. Tamoxifen) (a Companion Protocol to SWOG-8814 [INT-0100, CALGB-9194, EST-4188, NCCTG-883051, NCIC-MA.9])
Closed
Phase
Accrual
66%
Published
Abbreviated Title
Prognostic Factor Panel to Predict Preferred Therapy for Node Positive Postmenopausal Breast Cancer Patients (CAF vs. Tamoxifen) (a Companion Protocol to SWOG-8814 [INT-0100, CALGB-9194, EST-4188,…
Activated
02/01/1995
Closed
10/01/1998
Research committees
Breast Cancer
Publication Information Expand/Collapse
1998
Initial report of the SWOG biological correlative study of C-ERBB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone.
Other Clinical Trials
SWOG Clinical Trial Number
S2206
A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
S2212
TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
5%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007
A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase